RightFit
Not yet recruitingPhase 2

Vascular Intervention Strategies Trial for Alzheimer's

Vascular Intervention Strategies Trial for Alzheimer's (VISTA)

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
50 Years to 75 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

The proposed pharmacist-led study is a feasibility pilot trial for the management of vascular risk factors of hypertension and hypercholesterolemia in 10 APOE ε4 carriers, 50-75, at-risk for dementia. All participants will receive angiotensin receptor blockers (ARBs) for high blood pressure, and hydrophilic statins (or a non-statin alternative) for high cholesterol over a six-month period.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria: * APOE ε4 carrier (homozygote or heterozygote) * LDL-C of 100-250 mg/dL * Systolic blood Pressure (SBP) 130-180 mm Hg * Age 50-75 years * Fluency in English * No dementia based on medical record review * Male or post-menopausal female Exclusion Criteria: * One minute standing SBP \< 110 mm Hg * Arm circumference prevents from accurate BP measurement with use of available devices * Lost weight of \> 10% unintendedly (within the past 6 months), * Contraindications to blood pressure and cholesterol lowering medications * Use of medications prescribed for dementia (e.g., aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, memantine) * Evidence of dementia based on medical record review * Living in a skilled nursing or rehabilitation facility * Receiving palliative or hospice care * Bipolar illness or schizophrenia * Drug or alcohol disorder * Receiving chronic opioid therapy * Any significant neurological disease (e.g., Parkinson's disease, amyotrophic lateral sclerosis, or multiple sclerosis) * Severe loss of visual, hearing or communication ability * Organ transplant * History of stroke, symptomatic HF or left ventricular ejection fraction \< 35% * ESRD or eGFR \< 20 ml/min /1.73m2 * Does not consent to be contacted or to have their medical record reviewed for research purposes * Concurrent participation in another clinical trial

Study sites (1)

CA